Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
Cornelis M. van Tilburg(German Cancer Research Center), Olaf Witt(German Cancer Research Center), Claudia Rössig(University Hospital Münster), Jürgen Burhenne(Heidelberg University), Jonas Ecker(German Cancer Research Center), Kathrin I. Foerster(Heidelberg University), Bernd Gruhn(Jena University Hospital), Irini Karapanagiotou‐Schenkel(German Cancer Research Center), Till Milde(German Cancer Research Center), Dennis Riehl(European Molecular Biology Organization), Stefan M. Pfister(Heidelberg University), Michael C. Frühwald(University Hospital Augsburg), Christin Linderkamp, Juliane L. Buhl(German Cancer Research Center), Uwe Kordes(Universität Hamburg), Angelika Freitag(German Cancer Research Center), Felix Sahm(German Cancer Research Center), Lenka A. Taylor(Heidelberg University), Angelika Seitz(Heidelberg University), Arnulf Pekrun, Thorsten Simon(University of Cologne), Thomas Hielscher(Ontario Institute for Cancer Research), Regina Wieland(Essen University Hospital), Jens-Peter Schenk(Heidelberg University), Ruth Witt(German Cancer Research Center), Andreas D. Meid(Heidelberg University), Christian Flotho(University Medical Center Freiburg)
Cited by 44
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650